By Leora Borgenicht bio Before the healthcare industry can ambitiously transform to offer more accurate and personalized patient care, certain stepping stones must be reached. These four … [Read more...]
COMPLIANCE
Compliance Alert: FDA Warning Letter to Inova Genomics Laboratory
April 15, 2019
By Danielle Sloane bio and Elaine Naughton bio Despite it being a continual topic of discussion, the Food and Drug Administration ("FDA") enforcement in the realm of laboratory developed tests … [Read more...]
LEGISLATION
New Broad All-Payor Kickback Law Impacting Laboratories, Commission-based Compensation and more
January 14, 2019
By Danielle Sloane bio and Chris Climo bio In a recent piece of federal legislation intended to address the opioid crisis across the United States, Congress enacted a new all-payor kickback … [Read more...]
SPECIAL FOCUS
Evidence Building for Use of Liquid Biopsy to Drive Treatment Decisions, Monitor Disease Activity
December 31, 2018
Emerging evidence shows that liquid biopsy is a viable option for detecting and monitoring genomic mutations to inform treatment decisions and to assess disease activity in real-world clinical … [Read more...]
DATA
6 Steps to Data-Driven Transformation
November 26, 2018
By Nir Kaldero bio We're now well into the Fourth Industrial Revolution. The First Industrial Revolution was about steam and railroads, the Second about electricity, and the Third brought … [Read more...]
ECONOMIST SPEAKER
Labs Need to Take Elevated Role in Health Care
October 25, 2018
Labs need to take a more prominent role in the broader health care ecosystem—from being a recognized member of patient care teams to being a leading player in health system financial … [Read more...]
SPECIAL FOCUS
New Test Aids Lung Cancer Risk Assessment, But Survival Benefit of Comprehensive Sequencing Questioned
September 14, 2018
Lung cancer-related testing is receiving a lot of attention, but recent results appear to show mixed benefits for these emerging tests. There is an urgent need to improve lung cancer risk assessment, … [Read more...]
SPECIAL FOCUS
Cost Avoidance vs Cost Savings: What’s the Difference?
August 31, 2018
By Jennifer Dawson, MHA, DLM (ASCP) bio As I work to spread awareness within the clinical laboratory community about the Cost of Poor Quality (COPQ) concept and its benefits as a method to … [Read more...]
SPECIAL FOCUS
Noninvasive Gene Expression Test for Melanoma Cuts Costs
August 13, 2018
The noninvasive pigmented lesion assay (PLA; DermTech) reduces costs compared to the current standard of care for diagnostic workup of pigmented skin lesions suggestive of melanoma, according to a … [Read more...]
PRECISION MEDICINE
General Population Has Interest in Genetic Testing for Skin Cancer Risk
August 1, 2018
There is moderately high interest and follow through among the general population for genetic testing to determine melanoma skin cancer risk, according to a study published in JAMA Dermatology. … [Read more...]
